LM-108 — Investigational Agent
Monoclonal Antibody · Phase 3 · LaNova Medicines
Mechanism of Action
An anti-CCR8 monoclonal antibody engineered to selectively deplete tumor-infiltrating regulatory T cells via enhanced antibody-dependent cellular cytotoxicity, relieving immunosuppression in the tumor microenvironment, typically combined with a PD-1 inhibitor.
Investigational Indications
- CCR8-positive gastric/gastroesophageal junction adenocarcinoma
- Non-small cell lung cancer
- Triple-negative breast cancer